Access in all areas? A round-up of developments in market access and health technology assessment: part 14
Abstract
In this update we examine the selection of 15 drugs for the third cycle of Medicare price negotiations under the Inflation Reduction Act and analyze emerging evidence of the Most-Favored-Nation impact on global pharmaceutical access, including launch delays and market withdrawals. We also review recent research on the tension between US patient values and foreign health technology assessment frameworks and discuss the review of the first year of implementation of the Joint Clinical Assessment procedure in Europe.
Fields of Study & Subjects
Health Systems
Economic Evaluations
Quality of Life
Pharmaceutical Economics and Policy
Healthcare Systems and Reforms
Publication details
- Journal / source
- Journal of Comparative Effectiveness Research
- Publisher
- Becaris Publishing Limited
- Volume
- 15
- Issue
- 5
- Pages
- e260056–e260056
- Publication date
- 26 March 2026
- Language
- EN